JPRN-UMIN000010504已完成未知
Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel(nanoparticle albumin-bound paclitaxel) for the operable breast cancer (KSCOG-BC07) - Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel for the operable breast cancer (KSCOG-BC07)
Department of Surgery Kurume University School of Medicine0 个研究点目标入组 30 人开始时间: 2013年4月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Heart failure with clinically problem or history of cardiac dysfunction 2)Severe complication (uncontrolled diabetes, hypertension, renal failure, hepatic failure, Severe Infection and mental disorder which become problem on clinical practice) 3)Pregnancy and lactation or suspected pregnancy 4)Active secondary malignancy (current secondary malignancy or other malignancy within 5 years) 5)Bilateral breast cancer 6)Pulmonary fibrosis or pneumonitis 7)Allergy of the nab-Paclitaxel, Epirubicin,Cyclophosphamide and Fluorouracil 8)Physician judged improper to entry this trial
研究者
相似试验
已完成
2 期
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancerHER2 negative operable breast cancerJPRN-UMIN000008085Kinki Breast Cancer Study Group-Translational Research (KBCSG-TR)60
已完成
2 期
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancerHER2 negative operable breast cancerJPRN-UMIN000012909Kinki Breast Cancer Study Group-Translational Research (KBCSG-TR)120
已完成
不适用
PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancerHER2 positive resectable primary breast cancerJPRN-UMIN000008465Osaka Breast Cancer Chemo-Endocrine Therapy Study Group30
招募中
不适用
PhaseII trial of neoadjuvant chemotherapy with TS-1, Oxaliplatin and Bevacizumab for resectable liver metastases from colorectal cancerResectable colorectal liver metastasesJPRN-UMIN000004706agoya Surgical Oncology Group60
招募中
2 期
Phase II study of the neoadjuvant chemotherapy of GEM/nab-PTX for biological borderline-resectable pancreatic cancerC535836pancreatic cancerJPRN-jRCT1041230068Ebata Tomoki50